RxDoctor Payments Data

Jennifer Mokross

Primary Care · Coral Gables, FLNPI 1891183562

Payments from drug & device makers

$1,167in general payments, 2019–2025

Across 31 payments — averaging $37.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$344
  • Novo Nordisk$235
  • Edwards Lifesciences$164
  • GSK$151
  • E.r. Squibb & Sons, L.L.C.$102
  • Lilly USA, LLC$48
  • plus $123 from 5 others

What the payments were for

  • Food & beverage$1,167100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,167 in reported general payments places this provider in the 70th percentile of 725 primary care providers in Florida.

See all primary care providers in Florida

Medicare billing

Part B allowed, 2024
$20,354
Medicare patients
100
Services billed
333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide19$21,166
OzempicSemaglutide18$17,898
JanuviaSitagliptin Phosphate13$9,515
Breo ElliptaFluticasone/Vilanterol12$4,906
SynthroidLevothyroxine Sodium18$1,913
Rosuvastatin Calcium63$1,218
Atorvastatin Calcium78$811
Albuterol Sulfate HfaAlbuterol Sulfate37$757
Ciclopirox16$648
Omeprazole26$541
Temazepam45$506
Fluticasone Propionate38$481
Zolpidem Tartrate45$446
Clonazepam46$431
Metformin Hcl26$406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$48$21,16619 claims
Novo NordiskOzempic$235$17,89818 claims
GSKBreo Ellipta$151$4,90612 claims
AbbVieSynthroid$29$1,91318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 725 primary care providers in Florida.

Other primary care in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →